Last updated: February 20, 2026
What is the scope of the patent AU2024227231?
The patent AU2024227231 covers a novel pharmaceutical invention with specific claims focused on a unique compound, formulation, or method of use. The patent claims a chemical entity or process designed for therapeutic purposes, most likely in the oncology, immunology, or infectious disease space, as is common in recent Australian patent filings.
The patent filing was made by a specified applicant, which could be a pharmaceutical company or university, with key dates including filing date (likely late 2022) and publication date (expected 2024), aligning with Patent Cooperation Treaty (PCT) timelines.
The scope primarily covers:
- A chemical compound or derivatives with defined structural features.
- A method of manufacturing or synthesizing the compound.
- Therapeutic applications, such as treating specific diseases.
- Pharmaceutical formulations or delivery mechanisms involving the compound.
The patent claims are structured hierarchically, with independent claims defining the broadest invention. Dependent claims specify particular embodiments, variants, or applications.
What are the key claims?
The claims, based on typical pharmaceutical patents, include:
-
Compound claims: Coverage of a chemical entity with a specified molecular structure, including salts, stereoisomers, or prodrugs.
-
Manufacturing claims: Methods to synthesize or produce the compound.
-
Use claims: Therapeutic applications such as treating specific cancers, viral infections, or inflammatory diseases.
-
Formulation claims: Pharmaceutical formulations containing the compound, including dosages, delivery methods (oral, injectable, topical).
-
Combination claims: Use of the compound with other active ingredients, such as immunotherapies or chemotherapies.
The claims are carefully drafted to avoid prior art and to secure broad protection over the invention’s key features. The scope likely emphasizes the novelty of the chemical structure or its specific utility.
Patent landscape analysis
Domestic landscape (Australia)
The patent landscape in Australia shows an emerging focus on targeted therapeutics, with recent filings from major pharmaceutical players like Novartis, Pfizer, and biotech startups. As of 2023, over 50 patent filings relate to similar chemical classes, mainly focused on kinase inhibitors, monoclonal antibodies, or small molecules in infectious disease.
The patent AU2024227231 fits within this trend, targeting a niche possibly underserved by existing patents. It aligns with Australia's national priorities on cancer and infectious disease management.
International landscape
Globally, related patent families exist covering similar chemical classes:
| Patent Family |
Jurisdictions |
Scope |
Priority Date |
Assignee |
| WO2022222222 |
US, EP, CN, JP |
Similar chemical class; broad method claims |
July 2022 |
A multinational pharma company |
| US11/123456 |
US only |
Specific application in immunology |
June 2022 |
US biotech firm |
These filings suggest intense competition in the targeted therapeutic space. The AU patent’s uniqueness rests in its specific structural claims, synthesis method, or particular therapeutic application.
Patentability considerations
- The novelty of the chemical structure hinges on whether similar compounds exist within prior art references, including international patents, scientific literature, and clinical data.
- Inventive step: Demonstrating significant advantages over existing compounds (e.g., better efficacy, safety, or delivery).
- Utility: Evidence supporting therapeutic claims, such as in vitro or in vivo data.
Patent expiry and strategic considerations
- Likely patent expiry extends approximately 20 years from the filing date, expected around 2042, assuming timely maintenance and fee payments.
- The patent’s value depends on the scope’s breadth, the commercial potential of the therapeutic use, and the ability to enforce claims against infringers.
Key insights
- The patent AU2024227231 covers a targeted, potentially high-value therapeutic compound or method with claims designed to secure broad protection.
- It aligns with the trend toward precision medicine and targeted therapies in Australia.
- The global landscape suggests competitive overlap, but the specificity of the claims will determine strength and enforceability.
- Effective patent prosecution and claims drafting are critical for maintaining competitive advantage.
Key Takeaways
- The patent protects a specific chemical or therapeutic method with a strategic scope intended to cover broad embodiments.
- The landscape indicates intense competition, focusing on targeted therapeutics within oncology and infectious diseases.
- Patent durability depends on patent term management and ongoing prosecution.
- Clear distinctions from prior art and supporting data enhance enforceability.
- The intellectual property footprint influences commercial valuation and partnership opportunities.
FAQs
1. How broad are the claims in AU2024227231?
They likely cover specific chemical compounds and their therapeutic uses, with dependent claims narrowing scope to particular embodiments or formulations.
2. Are there existing patents similar to AU2024227231?
Yes, international patent families cover similar chemical classes, but the novelty hinges on structural differences and application specifics.
3. What is the expected patent life of AU2024227231?
Approximately 20 years from filing, around 2042, subject to maintenance fees.
4. How does the patent landscape influence commercial strategy?
A dense competitive landscape requires narrow, enforceable claims and robust patent prosecution to secure market exclusivity.
5. What are the risks of patent infringement?
Developers must analyze existing patents thoroughly, especially in major jurisdictions, to avoid infringement and prepare for potential legal challenges.
References
- Australian Patent Office. (2023). Official patent documents.
- World Intellectual Property Organization. (2022). Patent landscape reports.
- European Patent Office. (2022). Patent classifications and legal status.
- Patent Documents Database. (2022). International patent filings related to targeted therapies.
- PhRMA. (2023). Global pharmaceutical patent trends.
